NeuroOne Medical Technologies Files Q3 2024 10-Q

TL;DR

NeuroOne Medical Technologies filed its 10-Q for the quarter ending 12/31/24. Check financials.

AI Summary

NeuroOne Medical Technologies Corporation filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in Delaware with its principal executive offices in Eden Prairie, MN, operates in the surgical and medical instruments and apparatus sector. This filing provides an update on its financial performance and business operations for the specified quarter.

Why It Matters

This filing provides investors with crucial financial and operational details for NeuroOne Medical Technologies, impacting investment decisions and market perception.

Risk Assessment

Risk Level: medium — As a medical technology company, NeuroOne faces risks related to product development, regulatory approvals, market adoption, and competition.

Key Players & Entities

• NEUROONE MEDICAL TECHNOLOGIES Corp (company) — Registrant
• December 31, 2024 (date) — Quarterly Period End Date
• 001-40439 (other) — Commission File Number
• Delaware (jurisdiction) — State of Incorporation
• 27-0863354 (other) — I.R.S. Employer Identification Number
• 7599 Anagram Drive Eden Prairie, MN 55344 (address) — Principal Executive Offices
• 952 - 426-1383 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ange on Which Registered Common stock, $0.001 par value NMTC The Nasdaq Stock Market

Filing Documents

• ea0230295-10q_neuroone.htm (10-Q) — 558KB
• ea023029501ex31-1_neuroone.htm (EX-31.1) — 10KB
• ea023029501ex31-2_neuroone.htm (EX-31.2) — 10KB
• ea023029501ex32-1_neuroone.htm (EX-32.1) — 5KB
• ea023029501ex32-2_neuroone.htm (EX-32.2) — 5KB
• 0001213900-25-012511.txt ( ) — 4328KB
• nmtc-20241231.xsd (EX-101.SCH) — 50KB
• nmtc-20241231_cal.xml (EX-101.CAL) — 34KB
• nmtc-20241231_def.xml (EX-101.DEF) — 209KB
• nmtc-20241231_lab.xml (EX-101.LAB) — 414KB
• nmtc-20241231_pre.xml (EX-101.PRE) — 224KB
• ea0230295-10q_neuroone_htm.xml (XML) — 418KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Condensed Balance Sheets as of December 31, 2024 (unaudited) and September 30, 2024 1 Condensed Statements of Operations for the three months ended December 31, 2024 and 2023 (unaudited) 2 Condensed Statements of Changes in Stockholders' Equity for the three months ended December 31, 2024 and 2023 (unaudited) 3 Condensed Statements of Cash Flows for the three months ended December 31, 2024 and 2023 (unaudited) 4 Notes to Condensed Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32

– OTHER INFORMATION

PART II – OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 34 Item 6. Exhibits 34

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements NeuroOne Medical Technologies Corporation Condensed Balance Sheets As of December 31, September 30, 2024 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 1,134,350 $ 1,460,042 Accounts receivable 2,368,913 176,636 Inventory 1,930,861 2,635,153 Deferred offering costs 82,962 142,633 Prepaid expenses 194,699 216,461 Total current assets 5,711,785 4,630,925 Intangible assets, net 61,683 67,262 Right-of-use asset 339,271 254,910 Property and equipment, net 381,711 416,843 Total assets $ 6,494,450 $ 5,369,940 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 744,525 $ 1,029,206 Accrued expenses and other liabilities 826,386 1,184,014 Total current liabilities 1,570,911 2,213,220 Warrant liability 1,750,870 2,140,315 Operating lease liability, long term 237,377 194,392 Total liabilities 3,559,158 4,547,927 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding. — — Common stock, $ 0.001 par value; 100,000,000 shares authorized; 30,841,830 and 30,816,499 shares issued and outstanding as of December 31, 2024 and September 30, 2024, respectively. 30,841 30,816 Additional paid–in capital 76,123,542 75,795,610 Accumulated deficit ( 73,219,091 ) ( 75,004,413 ) Total stockholders' equity 2,935,292 822,013 Total liabilities and stockholders' equity $ 6,494,450 $ 5,369,940 See accompanying notes to condensed financial statements 1 NeuroOne Medical Technologies Corporation Condensed Statements of Operations (unaudited) For the three months ended December 31, 2024 2023 Product revenue $ 3,274,167 $ 977,649 Cost of product revenue 1,347,278 711,335 Product gross profit 1,926,889 266,314 License revenue 3,000,000 — Operating expenses: Selling, general and administrat

View Full Filing

View this 10-Q filing on SEC EDGAR